GSK, Haleon Stocks Drop After Setback on Zantac Cancer Litigation

Nearly four months after a federal court ruling eased investors’ anxieties around Zantac litigation, a decision by a state judge in California is reigniting those fears and rattling shares of drugmakers

GSK

and

Haleon

Late Thursday, the Alameda County judge overseeing a proceeding that combines roughly 2,000 Zantac cases filed in state courts in California issued a ruling that will allow expert witnesses to make certain arguments at a trial scheduled for July. The cases generally allege that the plaintiffs developed various forms of cancer after taking Zantac